NOVEL MUTANT L-ASPARAGINASES

摘要

The present invention relates to non-naturally occurring L-Asparaginases mutants particularly Type II Escherichia coli L-asparaginase (Ec A) mutants comprising at least one mutation in the amino-acid sequence of wild-type Ec A, wherein such mutation causes the mutants to induce significantly lesser immunogenicity, higher stability and higher cytotoxicity against leukemic cells as compared to wild-type Ec A. The present invention also provides use of the Ec A mutants as anti-leukemic agents for treatment of Acute Lymphoblastic Leukemia (ALL) in a subject in need thereof.